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Available online 12 August 2015AbstractHepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. It is recognized that the vast majority of HCC (90%)
develops in a hepatitis/cirrhotic setting, of which the early detection is very important. Pathologically, HCC develops in a multistage fashion in
the following steps: from regenerative nodules (RNs), low-grade dysplastic nodules (LGDNs), high-grade dysplastic nodules (HGDNs, the
premalignant phase, borderline lesions), nodule-in-nodule HCC, early small HCCs (eHCC, the early carcinoma phase, well-differentiated),
progressed small HCCs (pHCC, well to moderately-differentiated), and large HCCs (moderately to poorly-differentiated, so-called classical
HCC). Characterization of cirrhotic nodules on the basis of imaging and pathologic findings is complicated by an overlap in findings associated
with each type of nodule, a reflection of their multistep transitions. Recent progress in imaging modality, especially MRI, is starting to play a
crucial role in the evaluation of hepatocarcinogenesis, which facilitates detection and characterization in most cases of cirrhotic nodules. In this
review paper, we go over and detailedly illustrate the pathological features and MR imaging findings of these nodular lesions, and enable to
understand these nodules more completely, so as to accurately diagnose cirrhotic nodules.
© 2015 The Authors. Production and hosting by Elsevier B.V. On behalf of Beijing You’an Hospital affiliated to Capital Medical University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Liver cirrhosis is the strongest predisposing factor in he-
patocellular carcinoma (HCC), approximately 90% of HCC
cases develop in a cirrhotic liver [1]. HCC is becoming more
prevalent not only in Asia and Africa, but also in Western
countries. The incidence of HCC and its death rates have
increased gradually during the past 10 years, and the estimated
incidence of new cases is about 500,000e1,000,000 per year,
causing 600,000 deaths globally per year [2]. Worldwide,
HCC is already the fifth most common neoplasm and is the
third most common cause of death from cancer, after lung and
stomach cancers [3]. In China, the majority of HCCs are* Corresponding author.
E-mail address: lihongjun00113@126.com (H. Li).
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open access article under the CC BY-NC-ND license (http://creativecommons.org/associated with hepatitis B virus infection. Patients diagnosed
at an early stage are eligible for potentially curative therapies;
5-year survival rate is more than 50% in patients with small
HCCs [4]; however, very poor prognosis is observed with
advanced HCC (5-year survival rate below 10%). Therefore,
early detection of HCC is important, which helps improve
patient survival by allowing prompt detection and treatment.
At the macroscopic level, the carcinogenesis of HCC in
cirrhosis has been described as a multistep progression. The
cirrhosis-associated hepatocellular nodules are subdivided into
regenerative nodules (RNs), low-grade dysplastic nodules
(LGDNs), high-grade dysplastic nodules (HGDNs), nodule in-
nodule HCC, early small HCCs (eHCC, well-differentiated),
progressed small; HCCs (pHCC, well to moderately-
differentiated), and large HCCs (moderately to poorly-
differentiated), in an ascending order of histologic grades,
representing a sequence of multistep hepatocarcinogenesis.
The differentiation of these lesions is important because RNsf of Beijing You’an Hospital affiliated to Capital Medical University. This is an
licenses/by-nc-nd/4.0/).
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from regenerative and dysplastic nodules to HCC is not
characterized by discrete steps; rather, it is marked by a con-
tinuum of vascular pattern changes; the major changes that
characterize the progression are progressive loss of portal
vascularity and increased arterial blood flow. The presence of
overlapping features (even at the histopathologic level) of
some cirrhotic nodules makes their accurate characterization
difficult.
Currently, MRI is an ideal imaging modality for detection
and differentiation of focal cirrhotic nodules [5]. MRI pro-
vides various advantages [6], images can be obtained uti-
lizing various scan parameters or pulse sequences, adequate
information can be provided on. The T2-weighted fast spin-
echo sequence with fat suppression is a very sensitive
sequence for focal liver lesions. Chemical fat-saturation se-
quences and gradient-recalled echo (GRE) sequences with
out-of-phase and in-phase image acquisitions can be used to
detect hepatic or intra lesional steatosis. High-quality
multiphasic dynamic MRI allows more reliable imaging of
the liver in the arterial phase. Diffusion weighted images
(DWI) and liver-specific hepatobiliary contrast agents,
providing cellular information of the hepatocellular nodules.
These characteristics make MR successfully detect the
increasing size and vascularity of nodules, thereby providing
support for the concept of stepwise hepatocarcinogenesis.Fig. 1. Regenerative nodules in a 49-year-old woman with HBV-induced cirrhosi
renchyma, with slightly high signal intensity nodules of various sizes, which appear
intensity on T2WI with fat saturation (B), no enhancement at arterial phase (gado
rounding liver parenchyma at delayed phase (D). Photograph of explanted liver sh
Photomicrograph (original magnification, 40; hematoxylin-eosin [H-E] stain) of a
septa (F). (Adapted and reprinted, with permission, from reference 30 offered byFamiliarity with the multistep progression of cirrhotic nod-
ules and their MRI manifestations is therefore important for
optimal diagnosis and management. In this article, we review
the current classification of cirrhosis-associated hepatocel-
lular nodules, including HCC, as well as the associated
histologic and MRI manifestations.
2. Regenerative nodules2.1. Pathology of RNsRNs are the most common cirrhosis-associated hepatocel-
lular nodules, also known as cirrhotic nodules. They consist of
proliferating normal liver cells largely or completely sur-
rounded by fibrous septa (Fig. 1F), appear round and sharply
circumscribed [7], usually numerous and diffusely distributed
throughout the liver parenchyma, the outer liver surface may
be studded with nodules and deformed by them (Fig. 1E).
They resemble normal liver tissue but also show features of
regeneration such as twinning of cell plates, distortion of plate
architecture [5]. RNs may be monoacinar or multiacinar,
depending on whether they contain one or more terminal
portal tracts. RNs also may be classified into micronodular
(<3 mm), macronodular (>3 mm), and mixed types, on the
basis of the nodule sizes. Most RNs have diameters of less
than 2 cm. RNs with diameters of more than 2 cm are calleds. Unenhanced T1WI with fat saturation shows heterogeneity of the liver pa-
sharply circumscribed by hypointense septa (A). The nodules show low signal
linium-enhanced fat-saturated) (C), low signal intensity compared to the sur-
ows an outer surface studded with regenerative nodules of various sizes (E).
slice from the specimen shows the regenerative nodules surrounded by fibrotic
ZHANG Yan-yan).
Fig. 2. A large regenerative nodule (32 mm in diameter) in a 39-year-old man with HBV-induced cirrhosis. There is a subcapsular nodule at hepatic segment 3 (red
circle), which demonstrates slightly high signal intensity on T1WI with fat saturation (A), isosignal intensity to background liver parenchyma on T2WI with fat
saturation (B), similar enhancement to the surrounding parenchyma on arterial phase with fat saturation (C), and slightly low signal intensity on delayed phase (D).
Fig. 3. Dominant large regenerative nodule (50 mm in diameter). There is a subcapsular, large regenerative nodule in the left lobe of the cirrhotic liver (red circle),
close to the left portal vein and mimic a mass, which demonstrates slightly low signal intensity on T1WI (A) and T2WI with fat saturation (B); The nodule enhances
as much as surrounding parenchyma during the arterial phase with fat saturation (C), and shows slightly low signal intensity on delayed phase (D).
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rare and typically lack cytological or architectural atypia.
LRNs can measure 5 cm or larger and mimic a mass, they
usually locate near major vessels (Fig. 3AeD). Most RNs do
not progress in the dedifferentiation process. The blood supply
of a RN continues to be largely from the portal vein, with
minimal contribution from the hepatic artery [5]. This explains
why there is no enhancement on the hepatic arterial phase on
MR images.2.2. Imaging of RNsOn MR imaging, RNs are often indistinct on T1- and T2-
weighted images, better appreciated, when they are sharply
circumscribed within the liver parenchyma by fibrous septa.
The septa are relatively hypointense on T1-weighted images
and with isointensity on T2-weighted images. RNs are
usually iso-to hypointense on T2-weighted images, with
variable signal intensity (low, iso, high) on T1-weighted
images (Fig. 1A and B). RNs almost never show hyper-
intensity on T2-weighted images, except infarcted RNs [8]
that are uncommonly seen in cirrhotic patients notably
with before hypointensive shock and LRNs that are seen in
patients with long-standing Budd-Chiari syndrome [9] and
inpatients with cirrhosis due to autoimmune hepatitis [10].
Less commonly, they can be hyperintense on T1-weighted
images compared to background liver tissue. The exact
cause for this hyper intensity is unknown; it may be due to
the presence of lipids, metal-binding proteins, proteins per
se, or possibly copper [11].
RNs may occasionally contain endogenous iron (siderotic
nodules, the term was coined by radiologists), which will show
typically hypointense onT1- andT2-weighted images, a result of
their magnetic susceptibility [7]. Chemical shift imaging aids in
the diagnosis of siderotic nodules, showing drop of signal on the
sequencewith the longer echo-time (TE), which could be during
the in-phase or opposed phase, depending on the MR machine
used for imaging and its field strength, due to susceptibility ef-
fects resulting from proton de-phasing exerted by the presence of
iron. Siderotic nodules may be regenerative or dysplastic, but
neither unenhanced MRI findings (size, number, distribution)
nor contrast-enhanced MRI features permit reliable differentia-
tion between the two, therefore, the term siderotic nodule is now
favored. There is controversy over whether the occurrence of
HCC may increase in patients with siderotic nodules [12].
Siderotic RNs are not considered premalignant [7]. However, a
pathologic study also indicated that iron-accumulative DNsmay
associate with a higher incidence of HCC [13].
Another type of RN is steatotic. Steatotic RNs result from
fatty accumulation and tend to occur in multiples. Chemical
shift imaging aids also in the characterization of steatotic RNs.
They appear as hyperintense lesions on in-phase gradient
images and exhibit signal loss on out-of-phase images
(Fig. 4A and B) [5], due to destruction of the magnitude vector
within the same voxel, exerted by fat and water molecules
having opposite directions and resulting in decreased signal
intensity; indicative of intracellular (microscopic fat).Several studies have shown that nodules with high signal
intensity on T1-weighted images are in most cases benign
[14,15], a notable exception is fat-containing, a single large
size (>1.5 cm) nodule strongly suggests malignancy (Fig. 4).
Otherwise, the presence of numerous nodules <1 cm suggests
benignity [16].
Regardless of their intrinsic signal features, a reliable
finding of RNs is the absence of any detectable enhancement
on the arterial phase, compared with the background hepatic
parenchyma (Figs. 1e3) [5,8]. They have normal hepatocel-
lular and phagocytic functions and virtually all RNs enhance
to the same degree as adjacent liver on delayed T1-weighted
images after administration of hepatobiliary-specific [5,17],
which gives the liver a homogeneous appearance. Occasion-
ally, RNs may have sufficient hepatocellular function to take
up the hepatocellular agent but not to excrete it; such nodules
show hyperintense signal on hepatobiliary phase images.
Though most RNs usually show no interval growth or disap-
pear during serial imaging [15], RNs with a diameter of more
than 15 mm at imaging have an increased likelihood of being
dysplastic or malignant. However, an absence of early
enhancement after gadolinium administration, preserved up-
take of gadobenate dimeglumine suggestive of benignity. The
differential diagnosis between LRNs and low-grade DNs are
often found to be difficult, especially for the biopsied material,
as neoangiogenesis and cytological atypia are subtle in low-
grade DNs. Fortunately, this distinction does not appear to
have significant practical consequences at present.
3. Dysplastic nodules
Dysplastic nodules (from a few mm up to 2 cm, usually
1e1.5 cm, single or multiple) are evident on gross examina-
tion of hepatic specimens as distinct nodular lesions that differ
from the surrounding parenchyma with regard to size, color,
texture and bulging cut surface. DNs are usually, but not al-
ways, detected in cirrhotic livers with the incidence of 15%e
28% [5]. They are characterized histologically by progressive
architectural derangement, nuclear crowding, atypia, and a
variable number of unpaired arterioles or capillaries, classified
as LGDNs or HGDNs depending on the degree of cellular and
architectural atypias. LGDNs can evolve into HGDNs [18]. In
practice, histologic differentiation of LGDNs and HGDNs is
often very difficult, especially in biopsy [19], because the
portal and arterial supplies of these nodules are variable and
inconsistent.3.1. Pathology of LGDNsLGDNs are distinct from the surrounding cirrhotic liver
because of the presence of a peripheral fibrous scarwhich is not a
true capsule, but rather condensation of scarring around the
nodules. At histologic analysis, LGDNs are characterized by
preserved hepatic architecture, low-grade cytologic atypias,
slightly increased cell density, minimal nuclear atypia (Fig. 5I),
normal or slightly increased nuclear/cytoplasmic ratio, varying
numbers of portal tracts, absent mitotic figures, and very rare
Fig. 4. A large, fat-containing regenerative nodule in a 61-year-old man with HBV-induced cirrhosis, malignant transformation. There is a prominent right hepatic
nodule (21 mm in diameter) (red circle), which demonstrates minimally increaseT1 signal on the in-phase images (A), low signal intensity on the out-of-phase (B),
indicating the presence of fat. It shows low signal intensity on T2WI with fat saturation (C), part of the nodule enhances as much as surrounding parenchyma during
98 R. Li et al. / Radiology of Infectious Diseases 2 (2015) 94e108
the arterial phase, part shows no enhancement (Gadoxetic acid-enhanced with fat saturation) (D), and shows slightly low signal intensity on delayed phase (E), iso
and low signal intensity on hepatobiliary phase (F). 7 months later, the diameter of the lesion increases to 31 mm, but the prevalence of fat decreases. It dem-
onstrates slightly high signal intensity on the in-phase (G), iso to heterogeneous signal intensity on the out-of-phase (H), iso signal intensity on T2WI with fat
saturation in addition to a high point signal (white arrow) (I), which shows obvious enhancement at arterial phase (white arrow) (J), the other part of the lesion
enhances as much as surrounding parenchyma, at delayed phase, it shows low signal intensity (K). Histologic analysis showed it to be a steatotic high grade
dysplastic nodule.
Fig. 5. Low-grade dysplastic nodule in a 60-year-old man with HBV-induced cirrhosis. There is a 20-mm nodule in liver segment 5 (red circle), it shows high signal
intensity on the out-of-phase (A), low signal intensity on T2WI with fat saturation (B), no enhancement at arterial phase (gadolinium-enhanced fat-saturated) (C),
low signal intensity at delayed phase (D). The diameter of the lesion increases to 27 mm on the 5-month follow-up, but the MRI findings are similar to the previous
performance (EeH). Photomicrograph (original magnification, 100; H-E stain) shows low-grade cytologic atypias, slightly increased cellular, minimal nuclear
atypia in the nodule are indicative of low-grade dysplasia (I).
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so-called unpaired arterioles). LGDNs may have diffuse side-
rosis or increased copper retention, or uniform steatosis in livers
without fatty change. They closely resemble LRN histologi-
cally, distinction between them may be difficult or impossible.
LGDNs are considered to have low malignant potential with
slow, infrequent progression toHCC [20], should be followed up
and urgent treatment is not required. Intervals of screening are
only dictated by the growth rate of the tumor, which on average
takes six months to double its volume.3.2. Imaging of LGDNsSimilar to RNs, LGDNs show variable (low, iso or high)
signal intensity on T1-weighted images depending on their
content and low or iso signal intensity relative to adjacent liver
on T2-weighted images and demonstrate enhancement similar
to that of the background liver parenchyma on all dynamic
phases, without any detectable enhancement during arterial
phase (hypovascular nodules) (Fig. 5) [21], because the blood
supply is mainly derived from portal vein. The MR imaging
characteristics of LGDNs overlap with those of RNs, it is notFig. 6. High-grade dysplastic nodule in a 56-year-old man with HBV-induced cirrh
hypointense on T1WI (A), isointenseonT2WI with fat saturation (B), no enhancem
delayed phase (D), without restricted diffusion on DWI (isointense) (b ¼ 800 s/m
increased cellular and capillary density, a higher nuclear-cytoplasmic ratio, and
dysplasia (F).possible to differentiate LGDNs from RNs due to their similar
imaging features, but there are no significant practical conse-
quences [5,8].3.3. Pathology of HGDNsAt histologic analysis, HGDNs display at least moderate
cytologic and architectural atypia but insufficient for diagnosis
of malignancy. One or more of the following may be seen
(Fig. 6F): mild nuclear atypia, high nuclear-to-cytoplasmic
ratio, cytoplasmic basophilia or clear change, increased cell
density (1.3e2 times greater than that of adjacent cirrhotic
parenchyma), mildly thickened cell plates (two to three cells
wide), pseudoglandular formation, reduced numbers of portal
tracts, progressive sinusoidal capillarization, increased
numbers of unpaired arteries [22], forming subnodules within
dysplastic nodules. Such subnodules may demonstrate fatty
change, steatosis, Mallory body clustering, or iron resistance
(siderotic nodules [23]). Occasional subnodules may display
features that are diagnostic of well differentiated HCC and are
difficult to distinguish histologically, particularly those that are
small. HGDNs may even express a-fetoprotein (AFP) but areosis. There is a 27-mm nodule in liver segment 5 (red circle), it shows slightly
ent at arterial phase (gadolinium-enhanced fat-saturated) (C), hypointense at
m2) (E). Photomicrograph (original magnification, 100; H-E stain) shows
moderate architectural distortion in the nodule are indicative of high-grade
101R. Li et al. / Radiology of Infectious Diseases 2 (2015) 94e108not frankly malignant, they are the most advanced HCC pre-
cursors [21,24], with a risk of malignant transformation of
about30%e40% at 24 months. The size at baseline (larger the
nodule, higher the risk) and changes in size and/or in the
vascular pattern (shifting from hypo- to hyper-enhancing
pattern on arterial phase) during follow-up, were reliable
predictors of malignant transformation [25]. But most of
HGDNs remained stable over a long time period, often
exceeding two years and a few even disappeared at follow-up,
therefore, the treatment of HGDNs is under investigation.3.4. Imaging of HGDNsAt MR imaging, HGDNs demonstrate variable (low, inter-
mediate, or high) non-specific signal intensity on T1-weighted
images, depending on their content, and are usually iso- or
hypointense on T2-weighted images, a few percentage of
HGDNs tend to have slightly higher signal intensity on T2-
weighted images; Most of HGDNs are hypovascular
(Fig. 6AeE), minority can enhance in the arterial phase due to
the unpaired arteries (not in great numbers) and fade to iso
intensity [26], without washout (Fig. 7AeD), because supply
from the portal venous system remains comparable with the
background liver [27,21]. DNs and early HCCs cannot beFig. 7. High-grade dysplastic nodule progressing into a hepatocellular carcinoma. T
T1WI (A) and T2WI with fat saturation (B), slight enhancement at arterial phase (ga
8-month follow-up study, there is evidence of interval growth (28 mm in diameter
saturation (F), and development of obvious enhancement at arterial phase (gadoli
which are signs of progression into hepatocellular carcinoma.distinguished by unenhanced MR imaging alone, they may
show similar imaging findings on both extracellular contrast-
enhanced MR imaging and SPIO-enhanced MR imaging
[28]. Recently, Gadoxetic acid (Gd-EOB-DTPA), a tissue-
specific contrast material, seems promising tools to differen-
tiate early HCC from DNs [17]. Dynamic imaging can be
performed using this agent for hepatobiliary phase imaging
(10e20 min after injection) for the evaluation of functional
status. On hepatobiliary phases, HGDNs usually show an
efficient hepatocellular activity and often tend to appear iso- or
slightly hyperintense relative to surrounding parenchyma. In
some nodules impaired uptake and slow clearance of hepato-
cellular agents may justify hyperintense signal similar to a
focal nodular hyperplasia pattern characterized even by a
central scar. A few nodules may be hypointense due to
impaired uptake/excretion of hepatocellular agents, this
behavior may suggest malignant transition. When HGDNs are
seen as an increase in size and development of washout on
delayed phase or hepatobiliary phase, allowing definite diag-
nosis of HCCs (Fig. 7).
There is no typical imaging for HGDNs, needing all of
them to be biopsied for characterization. In addition to the
histological features which are necessary limited to the frag-
ment biopsied, false negative results are reported to rangehere is a 12-mm nodule in liver segment 5, it shows slightly hyperintense on
dolinium-enhanced fat-saturated) (C), no washout at delayed phase (D). On the
), and the nodule shows slightly hyperintense on T1WI (E) and T2WI with fat
nium-enhanced fat-saturated) (G), clear washout at delayed phase (H), all of
102 R. Li et al. / Radiology of Infectious Diseases 2 (2015) 94e108between 5% up to 30% at the first biopsy [29], hence, diag-
nosis of non-malignancy need to be confirmed by enhanced
follow-up. According to the latest guidelines from the Amer-
ican Association for the Study of Liver Diseases (AASLD),
DNs should not be treated or managed as cancers, patients
with known or suspected DNs should not be monitored more
aggressively than patients without such nodules [30]. As
HGDNs represent an intermediate step in the development of
HCC in cirrhotic liver [24], intensified screening is important
to identify liver cancer at the smallest possible size to optimize
treatment, though the screening intervals of DNs is 6 months
or 3 months is still questioned [31], we advise more frequent
surveillance imaging (usually 3 mo) despite the controversy.
4. Nodule in-nodule HCC4.1. Pathology of nodule in-nodule HCCThere is a morphologic continuity, a focus of well differ-
entiated HCC originates within a larger dysplastic nodule
referred to as a so-called “nodule-in-nodule” (this term is also
used for intra tumoral heterogeneity in HCC: the outer tumor
consists of well differentiated HCC tissue and the subnodule
showing expansive growth is moderately differentiated). TheFig. 8. HCC within a high-grade dysplastic nodule in a 54-year-old man with HBV-i
(17 mm in diameter) containing a smaller low-signal-intensity nodule in liver segm
hyperintense on T2WI (B), arterial phase image shows apparent enhancement of th
phase, the outer nodule shows non-washing-out, still slight hyperintense at delay
abnormality (white arrow) (E). Photomicrograph of a specimen (original magn
nodule (black arrows) (F). (Adapted and reprinted, with permission, from referencnodule-in-nodule pattern is uncommon, occurring in approxi-
mately 6% of patients with HGDNs [32].4.2. Imaging of nodule in-nodule HCCOn T1-weighted images, such lesions usually show high,
iso or low signal intensity of a large nodule, with internal foci
that are iso or low intense to the liver. On T2-weighted images,
the classic MR description is a low signal intensity of a large
nodule containing a focus of higher signal intensity, which
may demonstrate high signal intensity on DWI and enhance-
ment on arterial phase, low intense on hepatobiliary phase
(Fig. 8) [8,21], the remaining part of lesion (dysplastic nodule)
does not enhance on arterial phase and has lower signal in-
tensity, appear iso or slightly high signal intensity to sur-
rounding parenchyma on hepatobiliary phase.
5. Small HCC
As stated in2009 by the International Consensus Group for
Hepatocellular Neoplasia, small HCC is arbitrarily defined as
carcinoma measuring less than or equal to 2 cm in diameter
and classified in two types: one with indistinct margins known
as “HCC of vaguely nodular type” or “small and early HCC”nduced cirrhosis (nodule-in-nodule appearance). There is a hyperintense nodule
ent 6 on T1WI (A), the outer nodule shows isointense, the inner nodule shows
e whole nodule (C), but only the inner nodule shows clear washout at delayed
ed phase (D). Photograph of explanted liver shows a nodule-within-a-nodule
ification, 100; H-E stain) shows a HCC within the high-grade dysplasia
e 30 offered by ZHANG Yan-yan).
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“HCC of distinctly nodular type” or “small and progressed
HCC” (pHCC). At macroscopical level, the former is a low-
grade, early stage and slowly growing tumor of vaguely
nodular appearance and is hard to be recognized. Histologi-
cally eHCC is considered as well-differentiated cancer with a
little cellular and structural atypia, correspond to carcinoma in
situ of other organs. The distinctly nodular type is well
demarcated and often encapsulated, can be interpreted as
advanced cancer despite small tumor size, about 80% are
moderately differentiated form and the remnant 20% consist of
varying mixture and moderately differentiated cancerous tis-
sues. Smaller lesions are less likely to be associated with
microscopic vascular invasion and are more responsive to
curative treatments. Thus, HCCs should be diagnosed when
they are smaller than 2 cm.5.1. Pathology of early HCC (small well-differentiated
HCC or vaguely nodular type HCC)Early HCC may be invisible at gross specimen analysis and
detectable only with microscopy. On microscopic examina-
tion, early HCCs are well differentiated neoplasms, the his-
tologic features include [23]: relatively uniform population of
small cells with nuclear atypia and high nuclear/cytoplasmic
ratio; increased cell density (greater than that accepted in
HGDNs, more than twice that of the surrounding paren-
chyma); plates three or more cells thick; varying number of
portal tracts; irregular, thin trabeculae and/or pseudoglandular
pattern; diffuse fatty change; reduced number of trapped portal
tracts; increased number of unpaired arteries; stromal invasion
(tumor cell invasion into the intralesional portal tracts);
without vascular invasion and metastatic spread. Stromal in-
vasion remains most helpful in differentiating early HCC from
HGDNs because the features listed above may also be
recognized in HGDNs [33].
An important feature detected in approximately 40% of
cases is fatty change, a major clue calling attention to this
tumor type [34]. Fatty change is caused by relative hypoxia
due to cellular crowding and low blood supply. The prevalence
of fatty change decreases along with the increasing tumor size;
therefore, fatty change is uncommon in tumors larger than
3 cm and/or moderately differentiated HCCs. Early HCCs are
the earliest recognizable form of HCC, account for about
10%e20% of HCC, establishing a definitive diagnosis usually
requires a biopsy, most hypovascular HCCs and those with
equivocal imaging findings are early HCCs. They have a 5-
year survival rate of 89% [35,36], and have been found to
recur within 3 years of resection in only 8% of cases [36].5.2. Imaging of early HCC (small well-differentiated
HCC or vaguely nodular type HCC)A specific imaging diagnosis of early HCC arising in
cirrhosis is very difficult. On T1-weighted images, they mainly
demonstrate isointense or hyperintense, a small part appear
hypointense; on T2-weighted images, they usually appearslightly hyperintense, some may appear isointense or even
hypointense [20]. Cell crowding, fat accumulation and copper
deposition may be responsible for hyperintensity on T1-
weighted images; while hemosiderin, decreased blood supply
and/or reduced sinusoidal space was thought to be the cause of
hypo- or iso intensity on T2-weighted images [37]. A nodular
showing hyper intensity on T1-weighted images practically
narrows the differential diagnosis. In this setting, T2-weighted
images may aid in further differential diagnosis, since DNs are
usually of low signal intensity on T2-weighted images, while
early HCCs are typically either isointense or slightly hyper-
intense. Therefor, increased signal intensity of a nodule on
both T1- and T2-weighted images makes early HCC the most
likely diagnosis.
Early HCCs demonstrate relative arterial hypovascularity
(Fig. 9) (most are hypo- or isointense in the arterial phase) due
to the poorly developed neo-arterialization and decreased
portal supply, which is indicated by hypo intensity in the portal
phase, resulting therefore indistinguishable from HGDNs.
Such lesions are expected to demonstrate progressively
increased arterialization and a continued decrease in portal
blood until they become typical HCCs [27].
Some early HCCs show intense enhancement on dynamic
gadolinium-enhanced arterial phase MR images (Fig. 10).
Arterial hyper-enhancement is the most common and impor-
tant imaging finding in the diagnosis of HCC, but it can be
seen in HGDNs. The key distinguishing feature of HCC is the
development of delayed “washout”; defined as arterially
enhancing nodules becoming hypointense compared to the
background liver on the delayed phase imaging (not to be
confused with “fade out”, which is defined as arterially
enhancing nodules becoming isointense to background liver
on delayed phase imaging). A few early hypervascular HCCs
do not show washout on delayed images [29,38].
A recent report suggested that gadoxetic acid-enhanced MR
imaging may be useful for the improvement of the diagnosis
of early HCC [39]. On hepatobiliary-phase MR images, liver
parenchyma that contains functioning hepatocytes demon-
strates enhancement, and early HCCs that contain malfunc-
tioning hepatocytes demonstrate no enhancement and appear
as hypointense lesions [39]. However, well-differentiated
small HCCs may demonstrate enhancement on
hepatobiliary-phase images, a result of residual hepatocyte
activity and the reason for false-negative findings in some
cases. Morphological signs of malignance consider signal
hypo intensity and hyper intensity on T1- and T2-weighted
images, respectively; signal hyper intensity is also observed
on DWI related to higher cellular density. Finally, hypo in-
tensity on hepatobiliary phase is another valid sign.
Dynamic imaging is fundamental not only for nodule
characterization at baseline but also for the follow-up. Since it
is extremely difficult to perform biopsy of small nodules that
are smaller than 1 cm and visible only on arterial phase or
hepatobiliary-phase, close follow-up by imaging is recom-
mended according to American international practice guide-
lines [27,39]. These lesions should be re-examined at a 3-mo
interval to assess for lesions interval growth or development of
Fig. 9. Biopsy-proved hypovascular small early HCC in a 43-year-old man with HBV-induced cirrhosis. There is a 16-mm nodule in liver segment 8 (black arrow),
it shows slight hypointense on T1WI (A) and hyperintense on T2WI with fat saturation (B), poor arterial enhancement (gadolinium-enhanced fat-saturated) (C),
delayed washout with capsule enhancement (D). The diameter of the lesion increases to 25 mm on the 9-month follow-up, and the MRI findings are similar to the
previous performance (EeH).
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interval growth on short-term follow-ups does not exclude the
possibility of malignancy, only nodules that are stable for 2
years are considered benign [8]. Patient with liver nodule thatFig. 10. Small early HCC in a 70-year-old woman with HBV-induced cirrhosis. The
shows isointense on T1WI (A) and T2WI with fat saturation (B), increased arterial e
(black arrows).has a negative biopsy results should undergo repeated follow-
up at 3-6-month intervals until the nodule disappears, enlarges,
or has findings characteristic of HCC. If the lesion enlarges but
remains atypical for HCC, another biopsy is recommended.re is a 7-mm nodule in liver segment 7, it shows ambiguity due to ascites, may
nhancement (gadolinium-enhanced fat-saturated) (C), and delayed washout (D)
Fig. 11. Progressed small HCC in a80-year-old man with HBV-induced cirrhosis. There is a 20-mm nodule in liver segment 8 (black arrow), it shows hypointense
on T1WI (A), hyperintense on T2WI with fat saturation (B), obviously heterogeneous enhancement (gadolinium-enhanced fat-saturated) (C), and delayed washout
with capsule enhancement (D). DWI (b ¼ 800 s/mm2) shows restricted diffusion within the nodule (hyperintense) (E). Photomicrograph (original magnification, H-
E stain) of a specimen from the nodule shows advanced architectural distortion and nuclear atypia (F).
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differentiated HCC or distinctly nodular type HCC)Small and progressedHCCs (pHCCs) are usuallymoderately
differentiated, or consist of a mixture of well-differentiated and
moderately differentiated components. They have morphologic
and histologic characteristics similar to those of largeHCCs and
are easily differentiated from the background cirrhotic liver. It is
not a great diagnostic issue for radiologists and pathologists.
Histologic features include (Fig. 11F): advanced architectural
distortion (widening and irregularity of hepatocyte plates,
presence of pseudoglandular structures, absence of portal tracts,
numerous nontriadal arteries and well-developed sinusoidal
capillarization), nuclear atypia, necrosis, and microscopic in-
vasion of stroma and portal tracts. pHCC often forms sub-
noduleswith less cellular differentiation in the so-called nodule-
in-nodule form. Invasion of portal vein branches by tumor cells
and intrahepatic metastases have been described in 27% and
10% respectively [36] and are associated with a 5-year survival
rate of 48% [21,35].5.4. Imaging of progressed HCC (small moderately-
differentiated HCC or distinctly nodular type HCC)Progressed HCCs are small nodular lesions with charac-
teristics similar to those of classic HCCs and usually do notpose a diagnostic problem at MR imaging. These lesions tend
to be well-defined, homogeneous, and round or oval, with
variable signal intensity on T1-weighted images and, usually,
moderately hyperintense signal intensity on T2-weighted im-
ages. Most pHCCs demonstrate typical vascular pattern after
administration of gadolinium-based contrast material, with
enhancement in the arterial phase and washout in the portal or
delayed phase that becomes less intense than surrounding liver
(Fig. 11AeE) [35].
6. Large HCC (moderately to poorly differentiated HCC)6.1. Pathology of large HCC (moderately to poorly
differentiated HCC)Large HCC is defined as a tumor larger than 2 cm in
diameter [40] and tend to be characterized by moderate to poor
differentiation. Because of intra lesional steatosis, cholestasis,
hemorrhage, and lipofuscin, the color of large HCC typically
differs from that of the surrounding liver parenchyma, making
them readily identifiable at gross pathologic analysis. At his-
tologic analysis, large HCC is characterized by an abnormally
high number of muscularized, unpaired arterioles and capil-
larized vessels [20]. Large HCCs may exhibit a broad spec-
trum of morphologic features, including evidence of necrosis
and a mosaic pattern characterized by a seemingly random
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fibrous septa and areas of necrosis, a tumor capsule, an
intratumoral nodule (“nodule-in-nodule” appearance), extra
capsular extension with the formation of one or more satellite
nodules, vascular invasion, extra hepatic dissemination
(including lymph node and distant metastases) [26,41]. The
presence of extra capsular extension or macrovascular inva-
sion, and poor histologic differentiation are associated with a
higher risk of tumor recurrence after treatment.6.2. Imaging of large HCC (moderately to poorly
differentiated HCC)Some large HCCs have a characteristic MR imaging
appearance and are usually diagnosed with no difficulty. They
typically are hypointense on T1-weighted images and
moderately hyperintense on T2-weighted images, with arterial
intense enhancement and washout in the delayed phase.
Most large HCCs appear as mosaic pattern, which is a
configuration of confluent small nodules separated by thin
septa and necrotic areas within the tumor. This appearance
most likely reflects the histopathologic features of HCC, with
several centers of variable dedifferentiation, as well as the
characteristic growth pattern of HCC. They showFig. 12. Poorly differentiated large HCC with a mosaic pattern of enhancement in a
left lobe of liver, it shows hyperintense on T2WI with fat saturation (A), hetero
enhancement (mosaic pattern) (gadolinium-enhanced fat-saturated) (C), and delay
sion within the nodule (hyperintense) (B).heterogeneous lesions at MR imaging, have variable (iso-,
hyper-, or hypo-) signal intensity on T1-and T2 weighted
images, and demonstrate inhomogeneous enhancement after
administration of gadolinium-based contrast material (Fig. 12)
[5,8]. Better histologic differentiation, the presence of copper
protein, and fatty infiltration may all be responsible for the
hypersignal intensity on T1 weighted image. Intralesional fat
is characterized by signal intensity decrease on out-of-phase
images in comparison with in-phase images and low signal
intensity on fat-saturated images. The hemorrhage component
of HCCs is marked hyperintense on T1-weighted images and
hypointense on T2-weighted images. Intralesional necrosis
typically manifests as one or more areas of low signal intensity
on T1-weighted images and high signal intensity on T2-
weighted images with no enhancement [5].
A tumor capsule is a characteristic sign of large HCC, is
present in 60%e82% of cases [42], and it becomes thicker
within creasing tumor size. At histologic analysis, capsule is
composed of two layers, an inner fibrous layer and an outer
layer containing compressed vessels and bile ducts that ap-
pears as a thin circumferential rim around the periphery of the
tumor. The tumor capsule is usually hypointense on both T1-
and T2-weighted images in most cases with typical late
enhancement after administration of gadolinium-based47-year-old woman with HBV-induced cirrhosis. There is a large nodule in the
geneous enhancement with randomly distributed areas of hyper- and hypo-
ed heterogeneous washout (D). DWI (b ¼ 800 s/mm2) shows restricted diffu-
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than 4 mm can have an outer hyperintense layer on T2-
weighted images [42]. Delayed pseudo-capsule enhancement
of hepatic nodules aids in the diagnosis of HCC, and can be
helpful in lesions that do not show classical features of HCC
on dynamic imaging.
Extra capsular extension of the tumor, with partial pro-
jections or formation of satellite lesions is frequently seen in
large HCC (43%e77%) [41]. The satellite lesions often appear
as multiple subcentimeter nodules outside the tumor margins.
Vascular invasion occurs frequently in large HCC and can
affect both the portal vein as well as the hepatic veins [43].
Differentiation of tumor thrombus and nonneoplastic bland
thrombus is critical. A tumor thrombus, is indicative of HCC,
may be an important clue for the diagnosis of diffuse infil-
trating cancer and conveys a high risk of hematogenous
dissemination of cancer and precludes liver transplantation as
a treatment option. A bland thrombus is a frequent finding in
the setting of cirrhosis, may occur in the absence of HCC, and
maybe of minimal importance for decision making with regard
to the management, depending on its location and extent. At
MR imaging, vascular invasion can be seen as lack of a signal
void on T1-weighted and flow-compensated T2-weighted
images. On gadolinium-enhanced images, the tumor
thrombus typically expands the vascular lumen, enhances
during the arterial phase, and manifests as a filling defect
during delayed phase [26,41]. A nonneoplastic bland thrombus
does not enhance at the arterial phase and, instead of
expanding the lumen, causes it to contract.
About 10%e20% of HCCs are hypovascular (atypical
manifestations), typically, hypovascular HCCs are small, well-
differentiated tumors. Though rarely, an HCC that is larger
than 2 cm and poorly differentiated may be hypovascular [19].
Such lesions may be difficult to detect on gadolinium-
enhanced MR images despite their large size and aggressive
behavior, but they are usually visible on SPIO enhanced im-
ages. They characteristically accumulate less SPIO than the
surrounding liver parenchyma and have relatively high signal
intensity on T2-and T2*-weighted SPIO-enhanced images
[44]. A very few cases still require biopsy in order to make a
diagnosis [27].
7. Summary
In cirrhotic liver, HCC typically develops in a stepwise
fashion, including RNs, DNs, small HCCs, large HCCs.
Though most of RNs and DNs are benign, an understanding of
the histologic and imaging features is important because these
lesions may cause diagnostic confusion at MR imaging, with
resultant errors in interpretation and management. The
importance of pathologic-imaging correlation cannot be
overemphasized, not only on a daily diagnostic basis, but also
for the overall understanding and advancement of this field.
In this review paper, we went over the multistep process of
hepatocarcinogenesis, along with the histopathologic features
and the imaging findings associated with each stage, and hope
that these review articles will enhance the knowledge ofradiologists about current imaging modalities and various
contrast agents for the detection and characterization of
cirrhotic nodules, enable us to understand these nodules more
comprehensively and help us distinguish benign lesions from
premalignant and malignant ones.
Because of the similar morphologic criteria, differentiating
RNs from LGDNs, HGDNs from early HCCs on the basis of
dynamic imaging is still difficult, even for biopsy results, are
associated with a high rate of false-negative results. Imaging
diagnosis of hypovascular HCCs (absence of typical findings)
is also a challenge. We believe that the application of new
techniques, including molecular makers of hepatocellular
malignancy, newly developed tissue-specific contrast media
may overcome these limitations and increase the differential
diagnostic power among these hepatic nodules in the future.
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